Impact of heparin-induced thrombocytopenia on postoperative outcomes after cardiac surgery.

Ann Thorac Surg

Clinical Research Unit, Division of Cardiothoracic Surgery, Joseph B. Whitehead Department of Surgery, Rollins School of Public Health, Emory University School of Medicine, Atlanta, Georgia, USA.

Published: November 2007

AI Article Synopsis

Article Abstract

Background: The objectives of this study are to determine the effect of heparin-induced thrombocytopenia (HIT) on postoperative morbidity and mortality after cardiac surgery and to identify preoperative risk factors for HIT.

Methods: From 2002 to 2005, 487 cardiac surgery patients with postoperative thrombocytopenia (50% drop in platelet count or absolute count < 100,000/muL) underwent at least one enzyme-linked immunosorbent assay for HIT platelet factor 4 antibodies. Risk factors and outcomes of patients with a positive HIT assay (HIT+) were compared with patients with thrombocytopenia, but without HIT antibodies (HIT-).

Results: 23.2% of patients (113 of 487) were HIT+. Multivariable predictors of HIT included previous percutaneous coronary interventions (odds ratio [OR] = 1.76, p = 0.03), class IV New York Heart Association heart failure (OR = 1.80, p = 0.012), and infectious endocarditis (OR = 3.66, p = 0.0123). Postoperative infections occurred more frequently in HIT+ patients, including sepsis (16.8% versus 9.9%, p = 0.0433) and pneumonia (46.9% versus 23.3 %, p < 0.001). The HIT+ patients also had a higher rate of renal failure requiring hemodialysis (23.0% versus 9.1%, p < 0.001) and acute limb ischemia (15.9% versus 4.3%, p < 0.001). Thirty-day mortality was significantly higher in the HIT+ group (24.8% versus 15.2%, p = 0.019). Postoperative HIT emerged as an independent predictor of renal failure (OR = 1.73, p < 0.001) and thromboembolic complications (OR = 2.39, p = 0.02).

Conclusions: Heparin-induced thrombocytopenia patients are at significantly greater risk of thrombosis, renal failure, and mortality in the postoperative setting. Greater awareness of this devastating problem may allow earlier detection of HIT, with prompt institution of appropriate anticoagulation therapy, which could potentially limit the associated morbidity and mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2007.05.080DOI Listing

Publication Analysis

Top Keywords

heparin-induced thrombocytopenia
12
cardiac surgery
12
renal failure
12
thrombocytopenia hit
8
morbidity mortality
8
risk factors
8
hit+ patients
8
hit
7
patients
7
postoperative
6

Similar Publications

Danaparoid-Consensus Recommendations on Its Clinical Use.

Pharmaceuticals (Basel)

November 2024

Independent Researcher, 5345 MT Oss, The Netherlands.

(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations.

View Article and Find Full Text PDF

Background: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening adverse drug reaction with numerous diagnostic challenges. Diagnosis of HIT begins with 4T score clinical assessment, followed by laboratory testing for those not deemed low risk. Laboratory testing for HIT includes screening [enzyme-linked immunosorbent assay (ELISA)] and confirmatory [serotonin release assay (SRA)] assays, wherein SRA testing can be pursued following a positive ELISA result.

View Article and Find Full Text PDF

Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction with significant thromboembolic risk. Though there are models for use of non-heparin anticoagulants, heparin remains the preferred anticoagulant in many operative settings, especially cardiovascular surgery and percutaneous cardiac intervention. The natural history of HIT can be stereotyped into phases using HIT laboratory testing to guide clinical management and determine whether heparin re-exposure can be considered.

View Article and Find Full Text PDF

Background: Immunoglobulin G antibodies (Abs) to platelet factor 4 (PF4) complexed to heparin (PF4/H) commonly occur after H exposure but cause life-threatening complications of H-induced thrombocytopenia (HIT) in only a few patients. Presently, only platelet activation assays reliably distinguish anti-PF4/H Abs that cause disease (HIT Abs) from those likely to be asymptomatic (AAbs).

Objectives: Recent studies indicate that complement activation is an important serologic property of HIT Abs and is essential for IgG Fc receptor IIA-mediated cellular activation.

View Article and Find Full Text PDF

In-Hospital and Midterm Outcomes of Lead Extraction: A Single-Center Clinical Study.

J Tehran Heart Cent

January 2024

Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Background: The rate of lead extraction has steadily increased alongside the extensive use of cardiovascular implantable electronic devices. Data on the complications and safety of this challenging procedure are limited. We investigated inhospital and midterm outcomes following lead extraction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!